Radiology Research group photo

The University of Missouri School of Medicine Department of Radiology includes some of the nation’s leading scientists and clinicians in the areas of radiological imaging, therapeutics, chemistry, nanomedicine, and molecular medicine.

Basic Radiology Research

Our academic faculty have a diverse scope of interests including nano particle testing and the development of new imaging tracers for cancer detection and treatment. Their projects are industry sponsored, investigator initiated or funded through intramural grants. Overall, their combined work serves to understand and develop new technologies, processes, and chemical formulations that have the potential to translate into new medicines. They have been leaders in producing several widely used radiopharmaceuticals, including: Ceretec™, the first brain imaging agent; TheraSphere®, a treatment for liver cancer; and Quadramet®, an agent designed to relieve the excruciating pain associated with metastatic bone cancer. Some of the current trials are listed below:

  • Targeted Chemotherapeutics; PI: Raghu Kannan, PhD.
  • Clinical Translational Investigations of Nano-Phytomedicines; PI: Kattesh Katti, PhD.
  • Application of Green Nanotechnology for Enhanced Bioavailability and Odor Masking of the Energy Molecule (EM); PI: Kattesh Katti, PhD.
  • Metastatic Analysis of TRAMP Tumor Progression With/Without Therapeutic Treatment: Collaboration on MRI Data Analysis; PI: Lixin Ma, PhD.
  • Developing a Radiopharmaceutical Pipeline; Co-PI: C. Jeff Smith, PhD.
  • Tumor Aptamer Theranostics for Antigen Discovery, Immunotherapy, and Targeted Delivery; Co-PI: C. Jeff Smith, PhD.

Our researchers benefit from unique resources located on the MU campus:

In addition, many of our faculty have joint appointments at the Harry S. Truman VA Hospital which expands the population which our research can serve.

Clinical Radiology Research

Several of our clinical faculty are Principal Investigators (PI) on a number of industry sponsored or investigator initiated clinical trials. Though varied, these trials all serve to understand different diseases and/or treatments to provide better care for our patients at MU and for patients everywhere. Some of these trials are listed below:

  • Use of a Radiofrequency Chip for Localization of Non-Palpable Breast Lesions: A Comparison to Wire Localization; PI: Megha Garg, MD, Breast Imaging; IRB#2011684
  • Predictors for Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement; PI: Gregory Biedermann, MD, Radiation Oncology, IRB#2012045
  • Brain imaging markers of impaired clearance of Alzheimer’s markers in traumatic brain injury in soldiers in training; PI: Carlos Leiva Salinas, MD, Neuroradiology; IRB#2013615.
  • Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI); PI Ayman Gaballah, MD; Body Imaging; IRB#2014885-AA
  • Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI); PI: Megha Garg, MD, Breast Imaging; IRB#2015370-AA
  • Phase II Trial of Definitive Chemoradiation with Elective Nodal Irradiation Dose De-Escalation for P16 Positive Squamous Cell Carcinoma of the Oropharynx; PI: Gregory Biedermann, MD, Radiation Oncology, IRB#2017520
  • Quantifying Cardiac Motion Abnormalities on MR Exams using Principle Component Analysis; Grant PI: Steven Van Doren, PhD, Department of Biochemistry; Co-investigator: Robert Thomen, PhD, Department of Radiology; IRB#2016681
  • Trial of Propranolol in Children and Youth with ASD and Predictors of Response; PI: David Beversdorf, MD, Radiology and Neurology, IRB#2005213.